NI-1801 + pembrolizumab

NI-1801 + pembrolizumab is a combination therapy under investigation for the treatment of advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN), including platinum-resistant ovarian cancer. NI-1801 is an investigational agent being evaluated in early-phase clinical trials, while pembrolizumab is a highly selective humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor on lymphocytes. Pembrolizumab blocks PD-1 to prevent tumor cells from evading immune detection and destruction by T-cells. The combination aims to enhance anti-tumor immune responses by simultaneously targeting mesothelin-expressing tumors and inhibiting immune checkpoint pathways[4][5][6].

Other names

None